Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
This is a prospective, interventional, single arm, multicenter, phase 4 study to evaluate the clinical efficacy and safety of initiating Insulin glargine U300 in insulin-naive patients or switching from any other basal insulin to…
- Trial name
- INITIATION (NCT05002933)
- Testing
- Insulin glargine 300 U/ml
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin glargine as basal insulin therapy in adults with type 2 diabetes.
- Trial name
- IOPE (NCT00510952)
- Testing
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Where
- 17 sites in United States, Brazil and 2 more
- Volunteers
- 471 people
- Sponsor
- Eli Lilly and Company
Prediabetic State
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
Primary objective: To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e.
- Trial name
- RAPSODI (NCT00325650)
- Testing
- Rimonabant
- Where
- United States
- Volunteers
- 2,420 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes
The primary objective of the study is to demonstrate superiority of rimonabant/metformin combinations in Glycosylated Hemoglobin 1c (A1C) reduction over the corresponding single agent metformin and over rimonabant alone in…
- Trial name
- NCT00754689
- Testing
- Rimonabant, Metformin
- Where
- United States
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes
Type 2 diabetes results when the body does not produce enough insulin to regulate blood sugar. This study is designed to measure the effect of vildagliptin on the maximum insulin secretion by the pancreas.
- Trial name
- NCT00351585
- Testing
- Vildagliptin
- Volunteers
- 39 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effects of AZD1656 on Sitagliptin pharmacokinetics and vice versa in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01095991
- Testing
- AZD1656, Sitagliptin
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of IBI362 in Chinese patients with Type 2 Diabetes.
- Trial name
- NCT04965506
- Testing
- IBI362, Dulaglutide
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
T2DM (Type 2 Diabetes Mellitus)
To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus
This study aims to evaluate the efficacy and safety of initial combination therapy with DWP16001 and DWC202518 compared to DWP16001 monotherapy and DWC202518 monotherapy in patients with Type 2 Diabetes Mellitus
- Trial name
- NCT07619833
- Testing
- DWP16001, DWC202518
- Where
- South Korea
- Volunteers
- 510 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00039026
- Testing
- AC2993
- Where
- 126 sites in United States
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Weight Management, Treatment Of Obesity
A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes
- Trial name
- NCT00542009
- Testing
- CE-326,597 100 mg QD, CE-326,597 50 mg QD, CE-326,597 25 mg QD
- Where
- 54 sites in United States, Bulgaria and 5 more
- Volunteers
- 252 people
- Sponsor
- Pfizer
Type 2 Diabetes
WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to sulfonylurea alone or in combination with other anti-diabetic drugs.
- Trial name
- NCT00147758
- Testing
- Colesevelam hydrochloride
- Where
- 47 sites in United States, Mexico and 1 more
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes
The purpose of this study is to investigate (1) the effect of topiramate on insulin sensitivity in overweight or obese patients with type 2 diabetes mellitus and (2) the safety of topiramate in type 2 diabetic patients.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00236626
- Testing
- topiramate
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.
- Trial name
- NCT06370715
- Testing
- Insulin Lispro-aabc, Insulin Glargine
- Where
- 12 sites in India
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy
This study will assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy
- Trial name
- NCT00464776
- Testing
- Aliskiren
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 1
Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes
The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1…
- Trial name
- IOOZ (NCT00487240)
- Testing
- Insulin Lispro Protamine Suspension, Insulin Levemir
- Where
- 28 sites in United States, Argentina and 7 more
- Volunteers
- 387 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus
SY-009 is a novel compound that inhibits sodium glucose cotransporter-1 (SGLT-1). The preclinical and phase 1 clinical trial data support to carry out phase II clinical trial in diabetes subjects.
- Trial name
- NCT05426018
- Testing
- SY-009 capsules
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Type 2 Diabetes Mellitus (T2DM)
Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.
- Trial name
- NCT01131182
- Testing
- Sitagliptin phosphate, Comparator: Sulfonylurea, Metformin
- Volunteers
- 1,147 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus
Objectives: Primary Objectives To investigate the safety and tolerability of single ascending doses of AZP- 531 in healthy volunteers.
- Trial name
- NCT02040012
- Testing
- AZP-531
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Alizé Pharma
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes
This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.
- Trial name
- NCT07052292
- Testing
- DuraTouch®
- Where
- 11 sites in Poland
- Volunteers
- 128 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients
The purpose of this study is to evaluate the effect of BKR-017 on insulin resistance in type 2 diabetes (T2D) subjects during 28 days of active test product administration.
- Trial name
- NCT04279444
- Testing
- BKR-017
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- BioKier Inc.